Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 576 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Back
 Table of Contents
 
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed688    
    Printed28    
    Emailed0    
    PDF Downloaded87    
    Comments [Add]    

Recommend this journal

 
ARTICLE
Year : 1999  |  Volume : 41  |  Issue : 3  |  Page : 242-248

An Open Trial of Zuclopenthixol in Management of Acute Psychoses : A Multicentered Study


1 Director & Professor, Institute of Psychiatry & Human Behaviour, Goa, India
2 Professor and Unit Chief, Department of Psychiatry, Seth, G. S. Medical College & KEM Hospital, Mumbai, India
3 Assistant Professor, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, India
4 Additional Professor, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, India
5 Research Officer, Department of Psychiatry, Institute of Psychiatry & Human Behaviour, Goa, India
6 Research Officer, Department of Psychiatry, KEM Hospital, Mumbai, India
7 Research Officer, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore, India

Correspondence Address:
Partha Choudhary
Assistant Professor, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 21455397

Rights and PermissionsRights and Permissions

In an open trial, patients with ICD-10 diagnosis of acute functional psychoses were administered injection Zuclopenthixol acetate (Acuphase) in the initial phase. Patients were rated with CGI, BPRS-24 item and UKU side effect rating scale at baseJine, 24 hours and 72 hours. Of the 120 patients recruited, 119 finished this part of the trial. The most common side effect was sedation, which was preferable as most of the patients were in the acute state. The issues concerning less dosing efficacy and the rapid onset of antipsychotic activity are discussed. Patients who had been administered zuclopenthixol acetate in the acute phase were maintained with injection zuclopenthixol decanoate (depot) starting at 72 hours over the baseline. Patients were assessed at 72 hours, one week, 2 weeks, 3 vseeks, 4 weeks and 8 weeks using the same instruments. The issues concerning the dosage and therapeutic efficacy are discussed.



[PDF]*

        

Print this article         Email this article